| Name | Title | Contact Details |
|---|
ABK Biomedical Inc. combines a compelling clinical market need with innovative biomaterials invented by Drs. Bob Abraham, Daniel Boyd and Sharon Kehoe.
Clinomed Inc is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
T1D Exchange, a nonprofit organization, is a dynamic, multi-purpose, real-world patient data platform designed to accelerate all aspects of drug and device development. T1D Exchange has established a unique model to speed better treatments, therapies and research for type 1 diabetes (T1D). The Exchange consists of an integrated Clinic Network of 65+ clinics across the U.S., a Clinic Registry of 26,000 well-characterized patients, a Biorepository, and Glu, an online community with mobile capabilities for people touched by type 1 diabetes. The T1D Exchange fosters faster and more fluid information transfer and sharing among diabetes patients, physicians, researchers, and pharma, medical device, education, and outreach organizations.
Sound Technology Inc is a State College, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.